Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.042
Buy
RSI(14)
65.837
Neutral
STOCH(KDJ)(9,3,3)
68.145
Sell
ATR(14)
0.083
High Vlolatility
CCI(14)
111.809
Buy
Williams %R
37.991
Buy
TRIX(12,20)
2.172
Buy
StochRSI(14)
8.562
Sell
Search
Fractyl Health Inc
GUTSAdd to Watchlist
0.861USD
-0.093-9.79%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
136.53MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Fractyl Health Inc
Currency: USD Updated: 2026-05-15Key Insights
Fractyl Health Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 102 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.24.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Fractyl Health Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Fractyl Health Inc Highlights
StrengthsRisks
Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -0.46, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 126.15M shares, increasing 15.59% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 1.86M shares of this stock.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
5.240
Target Price
+449.27%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Fractyl Health Inc is 6.75, ranking 203 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 75.12%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.67
Operational Efficiency
2.67
Growth Potential
6.37
Shareholder Returns
7.03
Fractyl Health Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Fractyl Health Inc is 5.56, ranking 364 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.46, which is -63.51% below the recent high of -0.17 and -1309.87% above the recent low of -6.53.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 102/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Fractyl Health Inc is 8.40, ranking 127 out of 382 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 10.00 and a low of 5.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
5.240
Target Price
+449.27%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Fractyl Health Inc
GUTS
5
CRISPR Therapeutics AG
CRSP
27
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Fractyl Health Inc is 5.92, ranking 297 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.08 and the support level at 0.59, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.853
Buy
MA10
0.792
Buy
MA20
0.706
Buy
MA50
0.565
Buy
MA100
0.921
Sell
MA200
1.132
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Fractyl Health Inc is 7.00, ranking 83 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 79.56%, representing a quarter-over-quarter increase of 17.40%. The largest institutional shareholder is Lee Ainslie, holding a total of 4.25M shares, representing 2.68% of shares outstanding, with 69.13% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Fractyl Health Inc is 3.69, ranking 120 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+86.36%
240-Day Volatility
+160.58%
Return
Best Daily Return
60 days
+29.20%
120 days
+29.20%
5 years
--
Worst Daily Return
60 days
-9.79%
120 days
-68.04%
5 years
--
Sharpe Ratio
60 days
+3.57
120 days
+0.35
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+86.36%
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
-0.63
3 years
--
5 years
--
Skewness
240 days
-2.01
3 years
--
5 years
--
Volatility
Realised Volatility
240 days
+160.58%
5 years
--
Standardised True Range
240 days
+13.98%
5 years
--
Downside Risk-Adjusted Return
120 days
+31.80%
240 days
+31.80%
Maximum Daily Upside Volatility
60 days
+79.87%
Maximum Daily Downside Volatility
60 days
+50.51%
Liquidity
Average Turnover Rate
60 days
+4.78%
120 days
+8.59%
5 years
--
Turnover Deviation
20 days
+40.26%
60 days
+35.68%
120 days
+143.70%
Peer Comparison
Biotechnology & Medical Research
Fractyl Health Inc
GUTS
6.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
